Literature DB >> 10700541

Prenatal onset spinal muscular atrophy.

M J MacLeod1, J E Taylor, P W Lunt, C G Mathew, S A Robb.   

Abstract

Five patients with severe spinal muscular atrophy (SMA) type I, all of whom presented with reduced fetal movements in utero, severe weakness at birth, and short survival time were assessed to attempt to determine whether their phenotype could be explained by their genotype. The diagnosis was confirmed by clinical, electrophysiological and histopathological features. Polymerase chain reaction assays were used to define the molecular diagnosis. A gene-dosage assay was used to assess the quantity of centromeric survival motor neuron gene (SMNc) present. In all cases the telomeric survival motor neuron gene (SMNt) was absent. The SMNc gene was present but in reduced copy number compared with a control group of children with less severe type I SMA, so may be important in determining severity. In the differential diagnosis of reduced fetal movements, SMA should be considered. The clinical classification may in future be clarified by molecular genetic findings. Copyright 1999 European Paediatric Neurology Society.

Entities:  

Mesh:

Year:  1999        PMID: 10700541     DOI: 10.1053/ejpn.1999.0184

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  24 in total

1.  Spinal muscular atrophy--type I.

Authors:  M K M Hardart; R D Truog
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

Review 2.  Spinal muscular atrophy: state of the art and new therapeutic strategies.

Authors:  Sonia Messina; Maria Sframeli; Lorenzo Maggi; Adele D'Amico; Claudio Bruno; Giacomo Comi; Eugenio Mercuri
Journal:  Neurol Sci       Date:  2021-04-19       Impact factor: 3.307

Review 3.  Disease mechanisms and therapeutic approaches in spinal muscular atrophy.

Authors:  Sarah Tisdale; Livio Pellizzoni
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

Review 4.  Spinal Muscular Atrophy.

Authors:  Stephen J Kolb; John T Kissel
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

Review 5.  Spinal muscular atrophy: diagnosis and management in a new therapeutic era.

Authors:  W David Arnold; Darine Kassar; John T Kissel
Journal:  Muscle Nerve       Date:  2014-12-16       Impact factor: 3.217

6.  Plastin-3 extends survival and reduces severity in mouse models of spinal muscular atrophy.

Authors:  Kevin A Kaifer; Eric Villalón; Erkan Y Osman; Jacqueline J Glascock; Laura L Arnold; D D W Cornelison; Christian L Lorson
Journal:  JCI Insight       Date:  2017-03-09

7.  Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models.

Authors:  Jeong-Ki Kim; Narendra N Jha; Zhihua Feng; Michelle R Faleiro; Claudia A Chiriboga; Lan Wei-Lapierre; Robert T Dirksen; Chien-Ping Ko; Umrao R Monani
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

8.  Spectrum of neuropathophysiology in spinal muscular atrophy type I.

Authors:  Brian N Harding; Shingo Kariya; Umrao R Monani; Wendy K Chung; Maryjane Benton; Sabrina W Yum; Gihan Tennekoon; Richard S Finkel
Journal:  J Neuropathol Exp Neurol       Date:  2015-01       Impact factor: 3.685

9.  Review of Spinal Muscular Atrophy (SMA) for Prenatal and Pediatric Genetic Counselors.

Authors:  Amanda Carré; Candice Empey
Journal:  J Genet Couns       Date:  2015-08-08       Impact factor: 2.537

10.  DNA Damage Response and DNA Repair in Skeletal Myocytes From a Mouse Model of Spinal Muscular Atrophy.

Authors:  Saniya Fayzullina; Lee J Martin
Journal:  J Neuropathol Exp Neurol       Date:  2016-07-24       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.